- Home
- ADIL vs GLMD Comparison
ADIL vs GLMD Comparison
Compare ADIL & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- GLMD
- Stock Information
- Founded
- ADIL 2010
- GLMD 2000
- Country
- ADIL United States
- GLMD Israel
- Employees
- ADIL N/A
- GLMD N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- GLMD Health Care
- Exchange
- ADIL Nasdaq
- GLMD Nasdaq
- Market Cap
- ADIL 7.6M
- GLMD 7.5M
- IPO Year
- ADIL 2018
- GLMD 2014
- Fundamental
- Price
- ADIL $0.35
- GLMD $1.49
- Analyst Decision
- ADIL Strong Buy
- GLMD Hold
- Analyst Count
- ADIL 1
- GLMD 1
- Target Price
- ADIL $8.00
- GLMD N/A
- AVG Volume (30 Days)
- ADIL 562.1K
- GLMD 214.5K
- Earning Date
- ADIL 11-12-2025
- GLMD 11-13-2025
- Dividend Yield
- ADIL N/A
- GLMD N/A
- EPS Growth
- ADIL N/A
- GLMD N/A
- EPS
- ADIL N/A
- GLMD N/A
- Revenue
- ADIL N/A
- GLMD N/A
- Revenue This Year
- ADIL N/A
- GLMD N/A
- Revenue Next Year
- ADIL N/A
- GLMD N/A
- P/E Ratio
- ADIL N/A
- GLMD N/A
- Revenue Growth
- ADIL N/A
- GLMD N/A
- 52 Week Low
- ADIL $0.22
- GLMD $1.15
- 52 Week High
- ADIL $1.30
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- ADIL 36.98
- GLMD 51.48
- Support Level
- ADIL $0.36
- GLMD $1.42
- Resistance Level
- ADIL $0.38
- GLMD $1.60
- Average True Range (ATR)
- ADIL 0.02
- GLMD 0.10
- MACD
- ADIL 0.00
- GLMD 0.03
- Stochastic Oscillator
- ADIL 14.00
- GLMD 68.06
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.